Last reviewed · How we verify
High dose erythropoietin
High-dose erythropoietin stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels.
High-dose erythropoietin stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia of chronic disease.
At a glance
| Generic name | High dose erythropoietin |
|---|---|
| Also known as | High dose |
| Sponsor | VA Office of Research and Development |
| Drug class | Erythropoiesis-stimulating agent |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Erythropoietin (EPO) is a cytokine that binds to the erythropoietin receptor on erythroid progenitor and precursor cells, promoting their proliferation, differentiation, and survival. At high doses, it can enhance oxygen-carrying capacity of blood by increasing red blood cell mass. This mechanism has been explored therapeutically for anemia and experimentally for tissue protection in conditions with hypoxic injury.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in cancer patients receiving chemotherapy
- Anemia of chronic disease
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Fever
- Pure red cell aplasia
- Seizures
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy (PHASE3)
- High Dose of Erythropoietin Analogue After Cardiac Arrest (PHASE3)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage (PHASE1)
- Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies (PHASE2)
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects (PHASE3)
- A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose erythropoietin CI brief — competitive landscape report
- High dose erythropoietin updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI